ANI Pharma (ANIP) Launches Nitazoxanide Tablets
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- S&P 500, Dow futures dip as big banks' earnings roll in ahead of CPI data; IBM slides
- IBM plunges 19% as memory capex squeeze derails Q2 earnings
- SK Hynix’s record plunge drags down global chip stocks
- Software stocks tumble: High memory prices cannibalize enterprise tech capex
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- IBM misses Q2 targets as mainframe and software sales disappoint
- Goldman Sachs Upgrades NIO (NIO) to Buy
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- BofA Securities on AppLovin: 'Current valuation appears reasonable'
- YPF Energía Eléctrica S.A. files for proposed NYSE IPO
ANI Pharmaceuticals Announces the Launch of Nitazoxanide Tablets
March 19, 2025 6:50 AM EDTPRINCETON, N.J., March 19, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Nitazoxanide Tablets, 500 mg. ANIs Nitazoxanide Tablets are the generic version of the reference listed drug (RLD) Alinia®.
"The market launch of Nitazoxanide Tablets, another niche limited competition product, underscores our purpose of Serving Patients, Improving Lives, stated Nikhil Lalwani, President and Chief Executive Officer of ANI.
"We share ANIs commitment to providing affordable, high-quality medicines for the patients who depend on them and are... More
